Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology. Its business currently combines royalty income from AbbVie’s HCV franchise with an internal pipeline spanning RSV, hepatitis B, and type 2 inflammatory diseases such as atopic dermatitis and CSU.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCash royalties tied to AbbVie sales of MAVYRET/MAVIRET, based on Enanta's licensed HCV protease inhibitor assets.
Clinical-stage programs aimed at treating respiratory syncytial virus infection, including zelicapavir and EDP-323.
Preclinical small-molecule programs targeting type 2 immune diseases through STAT6 inhibition.
In-licensing, out-licensing, and collaboration activities that monetize or expand the pipeline.
Customers
Enanta does not currently sell approved products directly to patients or physicians; its near-term commercial customer is primarily AbbVie through the collaboration and royalty structure. For future pipeline assets, the eventual buyers would be hospitals, physicians, payers, and patients in infectious disease and immunology markets, but those products are still in development. The company also works with third-party licensors, manufacturers, and research partners to advance and monetize its programs.
AbbVie commercializes MAVYRET/MAVIRET and pays Enanta royalties tied to HCV sales.
Physicians, hospitals, and clinics that would prescribe zelicapavir or EDP-323 if approved.
Insurers and managed care organizations that determine access and pricing for any approved drug.
Pharma or biotech partners that may in-license, co-develop, or commercialize Enanta assets.
Strategy
Enanta’s strategy is to use royalty cash flow from AbbVie to fund discovery and clinical development of new virology and immunology assets. The company is prioritizing RSV and type 2 inflammation programs while preserving flexibility to in-license, out-license, or partner assets depending on scientific fit and capital needs. Because it has no internal sales force, commercialization is expected to rely on partners unless a program becomes sufficiently advanced to justify a different route.
RSV is a large unmet-need market where clinical success could create partnering or commercialization value.
STAT6 inhibition could open a second therapeutic franchise beyond virology and diversify pipeline risk.
Licensing can generate non-dilutive capital and reduce the need to build a full commercial organization.
Geography
Enanta is headquartered in Watertown, Massachusetts and operates as a U.S.-based R&D company. Its business is globally exposed through AbbVie’s international HCV sales and through third-party manufacturing, including suppliers in China for active pharmaceutical ingredients and clinical trial materials. Because it has no internal commercial infrastructure, geography matters mainly through partner sales markets, supply chain sourcing, and regulatory jurisdictions.
Risks
Enanta is exposed to clinical development risk, partner concentration risk, and dependence on royalty income from a single marketed asset family. Its pipeline is still early enough that efficacy, safety, regulatory, and reimbursement outcomes remain uncertain, while manufacturing relies heavily on third parties. The company also faces industry-wide competition from larger pharma and biotech firms with greater resources and more advanced programs.
- Dependence on AbbVie royalty revenueImpact: HighLikelihood: High
A large share of current cash generation comes from MAVYRET/MAVIRET sales, so any decline in HCV demand directly reduces funding for R&D.
Exposure: AbbVie HCV collaboration
- Clinical development failureImpact: HighLikelihood: Medium
Zelicapavir, EDP-323, and STAT6 programs are still in development and may not show sufficient efficacy or safety.
Exposure: RSV and immunology pipeline
- Third-party manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
The company relies on external manufacturers, including in China, for APIs and clinical supply.
Exposure: API sourcing and clinical trial materials
- Reimbursement and pricing pressureImpact: MediumLikelihood: High
Even approved drugs may face payer resistance, limiting uptake and realized economics.
Exposure: Future commercial products
- Competition from larger pharma and biotech companiesImpact: MediumLikelihood: Medium
Competitors have greater resources, late-stage assets, and established commercial infrastructure.
Exposure
Accounting
Judgemental itemsRevenue is driven by AbbVie net sales and tiered royalty terms, so timing and contract interpretation affect reported revenue.
Impact: Affects top-line volatility and comparability across periods
Only 45.5% of certain royalty cash flows are retained, changing cash conversion versus reported revenue.
Impact: Affects liquidity and cash flow analysis
Clinical, preclinical, and manufacturing costs are estimated and accrued before invoices are finalized.
Impact: Can shift quarterly operating expense and margin
The liability is measured using unobservable inputs and could change with valuation assumptions.
Impact: Affects balance sheet and non-cash fair value adjustments
Similar listed companies
Publicly listed companies with a comparable business focus.
Atea Pharmaceuticals, Inc.
AVIR · Pharmaceutical Preparations
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Innoviva, Inc.
INVA · Pharmaceutical Preparations
Enliven Therapeutics, Inc.
ELVN · Pharmaceutical Preparations
Cocrystal Pharma, Inc.
COCP · Pharmaceutical Preparations
Last updated: 24/09/2026